Agency notice: FDA proposes withdrawing approval for Flolipid suspension
Federal · applicability depends on the document
The FDA is proposing to withdraw approval of NDA 206679 for Flolipid suspension in 20 milligrams/5 milliliters and 40 milligrams/5 milliliters.
The agency says the proposal follows Salerno Pharmaceuticals’ repeated failure to file required annual reports for the application.
Salerno Pharmaceuticals may request a hearing on the proposal.
Based on the linked record from Federal Register ↗. Our reporting and verification standards.
Source, dates and supporting record
- Source published
- Nov 18, 2026
- Last checked
- Nov 19, 2026, 2:45 PM EST
- Record status
- Agency notice
- Comment deadline
- Jan 19, 2027
Supporting excerpts
The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of new drug application (NDA) 206679 for Flolipid suspension, 20 milligrams (mg)/5 milliliters (mL) and 40 mg/5 mL and is announcing an opportunity for the NDA holder, Salerno
The basis for the proposal is that Salerno Pharmaceuticals has repeatedly failed to file required annual reports for NDA 206679.
Pharmaceuticals, 2431 East 61st St., Suite 300, Tulsa, OK 74136, to request a hearing on this proposal.
Original source text
Source wording and its time zone may differ. Date-only dates are preserved. Timestamps here use Eastern Time. Evidence version: c607434c77ee11932eb460501ae78a56c1a07e3bf01c1bbd19724b11da85959e
Source guidance
Original guidance from the issuing source. For current warnings and instructions, consult that source directly. This site is not an emergency notification service.
